Pliant Therapeutics (PLRX) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Talphera (TLPH) has outperformed Pliant Therapeutics (PLRX) over the past year, losing 41.4% versus a loss of 61.6%. Over five years, TLPH leads with a -94.0% price change compared with -95.9% for PLRX. Talphera is the larger company by market cap ($40.8 million vs $36.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PLRX | TLPH |
|---|---|---|
| Share price | $0.5951 | $0.7852 |
| Market cap | $36.89M | $40.80M |
| 1-day change | -4.02% | +6.25% |
| YTD return | -51.22% | -31.12% |
| 1-year return | -61.61% | -41.40% |
| 5-year return | -95.89% | -93.96% |
| EPS (TTM) | $-1.46 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $28.00K |
| Net income (latest FY) | $-149.34M | $-14.29M |
| Operating margin | — | -48157.14% |
| Net margin | — | -51035.71% |
| 52-week high | $1.67 | $1.57 |
| 52-week low | $0.5719 | $0.69 |
| Distance from 52-week high | -64.37% | -49.99% |
| Analyst consensus | none | none |
| Avg. price target upside | +236.08% | +298.62% |
| Average volume | 408.93K | 144.13K |
| Shares outstanding | 61.99M | 51.96M |
| Employees | 49 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TLPH has outperformed PLRX by 20.2 percentage points over the past year.
About Pliant Therapeutics
PLRX stock →Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
PLRX vs TLPH FAQ
Which is bigger, Pliant Therapeutics or Talphera?
Talphera (TLPH) is larger, with a market capitalization of $40.80M compared with $36.89M for Pliant Therapeutics (PLRX).
Which stock has performed better over the past year, PLRX or TLPH?
TLPH returned -41.40% over the past 12 months, compared with -61.61% for PLRX (price return, excluding dividends). Past performance does not predict future results.
Are Pliant Therapeutics and Talphera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.